A little could mean a lot

With a BLA submission due before year end for its Rhucin to treat hereditary angioedema, Pharming Group N.V. looks to have made a small potatoes deal when it granted Santarus Inc. North American commercialization rights to the product this month. But Pharming CEO Sijmen de Vries believes the company's growth picture lies downstream from the product's first approvals in the HAE space, where four products will be battling for market share.

Given Pharming's €9.8 million ($12 million) in cash at June 30 and six-month operating loss of €12.1 million ($14.9 million), de Vries said company needed to do a deal...